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Introduction
Meropenem is a new antimicrobial agent belonging to the carbapenem group. Imipenem and panipenem were the first representatives of this group of antibiotics available for clinical use. Both imipenem and meropenem are now marketed in The Netherlands and were introduced in July 1986 and August 1995, respectively. Other carbapenem antibiotics, such as biapanem, 1 are currently under investigation but not yet available for clinical use.
Imipenem and panipenem are readily hydrolysed in vivo by human renal dehydropeptidase-I (DHP-I) and therefore have to be co-administered with dehydropeptidase inhibitors like cilastatin 2 or -mipron.
Thirty microbiology laboratories throughout The Netherlands collaborated in this survey, which included 2169 strains. Only isolates from blood (n 516), sputum, including broncho-alveolar lavage (n 839), pus, including intra-abdominal, pleural, skin and soft tissue and bone aspirates (n 789), and cerebrospinal fluid (n 25) were included in the study. All strains were isolated from the focus of infection of hospitalized patients with serious infections requiring antimicrobial treatment. Only one isolate per species per patient was included, with a maximum of eight isolates per species per centre.
All isolates were collected between October 1994 and April 1995 and belonged to the following species: Escherichia coli (n 174), Proteus mirabilis (n 134), Proteus vulgaris (n 24), Morganella morganii (n 124), Klebsiella oxytoca (n 72), Klebsiella pneumoniae (n 106), Enterobacter cloacae (n 142), Enterobacter aerogenes (n 26), Citrobacter freundii (n 90), Citrobacter diversus (n 34), Serratia marcescens (n 120), Serratia liquefaciens (n 18), Pseudomonas aeruginosa (n 171), Acinetobacter spp. (n 87), Haemophilus influenzae (n 173), methicillin-susceptible Staphylococcus aureus (n 179), coagulase-negative staphylococci (CNS) (n 166), Enterococcus faecalis (n 153), Enterococcus faecium (n 10) and Streptococcus pneumoniae (n 166).
The following antimicrobial agents were tested for Gram-negative organisms: meropenem, imipenem, ticarcillin/clavulanic acid, piperacillin/tazobactam, co-amoxiclav, ciprofloxacin, gentamicin, cefuroxime, cefotaxime and ceftazidime; the following were tested for Grampositive organisms: meropenem, imipenem, piperacillin/ tazobactam, ciprofloxacin, gentamicin, erythromycin, clindamycin, vancomycin, penicillin, oxacillin (for staphylococci) and amoxycillin (for streptococci).
All media were purchased from one manufacturer (Oxoid Ltd, Basingstoke, UK) and distributed to the participating centres. PDM agar was chosen as standard test medium. Five per cent sheep blood was added for testing S. pneumoniae; 1% haemoglobin and Isovitalex (Oxoid Ltd) were added for testing H. influenzae; Mueller-Hinton agar supplemented with 2% NaCl was used for testing of all staphylococci for oxacillin, penicillin, meropenem, imipenem and piperacillin/tazobactam. 9 The antimicrobial activity was measured with the Etest (AB Biodisk, Solna, Sweden). Extended-spectrum -lactamase (ESBL) production in E. coli and K. pneumoniae was tested at the coordinating laboratory with the Etest. ESBL production was suggested when reversal of resistance to ceftazidime by clavulanic acid was found. The standard inoculum was 0.5 McFarland except for oxacillin, penicillin, meropenem, imipenem and piperacillin/tazobactam testing of staphylococci. For these susceptibility tests an inoculum of 1 McFarland was prepared. 9 Plates were incubated at 35-37°C for 18-24 h. The National Committee for Clinical Laboratory Standards breakpoints for susceptibility and resistance were used. 10 The meropenem breakpoints for all species were: 4 mg/L, susceptible; 16 mg/L, resistant, except for H. influenzae and S. pneumoniae. For H. influenzae the breakpoints used were: 4, susceptible; 8 resistant; and for S. pneumoniae: 0.12, susceptible; 1, resistant. These are the same as the values recommended for imipenem by the NCCLS. Etest strips are marked in 0.5 log 2 concentrations. The NCCLS reference methods and breakpoints are based on two-fold dilutions. Therefore, for the calculation of percentage of susceptible and resistant strains (Tables I-III) using the NCCLS breakpoints, the Etest MIC was rounded to the nearest higher log 2 dilution.
The MICs were determined for the following reference strains by all participating laboratories: E. coli ATCC 25922, P. aeruginosa ATCC 27853, S. aureus ATCC 29213 on all testing days. The MICs received from the participating centres were included in the study database only when the MICs of the reference strains were in agreement with accepted quality control ranges of MICs. For validation of MICs for H. influenzae and S. pneumoniae, two strains per species per centre were randomly selected and retested at the Rotterdam co-ordinating laboratory using H. influenzae ATCC 49247 and S. pneumoniae ATCC 40619 as control strains. The MICs for all H. influenzae and S. pneumoniae from a participating laboratory were included in the database when the MICs for the strains retested at the co-ordinating laboratory were within two log 2 dilution steps of the MICs performed at the participating laboratory, and the MICs for reference strains fell within the accepted quality control ranges of MICs.
The chi-square test with the Yates' correction was used to analyse differences in the frequency of resistances (Table III) .
Results
The activity of meropenem and 15 other antimicrobial agents against 1437 Gram-negative microorganisms (Table I ) and 674 Gram-positive (Table II) were compared. The MICs obtained for P. vulgaris (n 24) were almost identical to those obtained for M. morganii. C. diversus (n 34) was more susceptible to co-amoxiclav than C. freundii: 76% versus 21%, respectively. E. faecium (n 10) was in general more resistant to several antimicrobial agents when compared with E. faecalis: imipenem MIC 90 A group of Enterobacteriaceae that share chromosomal Class I -lactamases was pooled in a subgroup called 'potentially inducible' Enterobacteriaceae (E. 
Discussion
This study differs from several others in that stringent selection criteria for inclusion of strains were used. The collection of isolates represents well-defined clinically relevant isolates, since neither contaminant nor colonizing or double isolates from the same patient were included in the study. In general, in comparison with imipenem, meropenem was one-to six-fold less active against Gram-positive organisms with the exception of E. faecalis. In contrast, against Gram-negative organisms meropenem was found to be two-to 24-fold more active with the exception of Acinetobacter spp. This is roughly in agreement with the compiled data presented by Edwards 11 , except for E. faecalis and Acinetobacter spp. Surprisingly, the meropenem MIC 90 for E. faecalis was 32 mg/L and fourfold higher than that in other studies.
11,12 Therefore, the MIC as well as the identification of all enterococci was retested at the co-ordinating laboratory using Etest and standard identification criteria. 13 The high MIC 90 for E. faecalis was confirmed. Further studies into the mechanism of meropenem resistance in enterococci is currently in progress. The high MICs of meropenem and imipenem (MIC 90 32 mg/L) for E. faecium are in agreement with previous studies. 11, 12 No difference in susceptibility was observed between strains isolated from blood and CSF compared with those isolated from sputum and pus.
The prevalence of MRSA is very low in The Netherlands. Therefore, no methicillin-resistant S. aureus isolates were included but 25% of the S. aureus strains were susceptible to penicillin. In a recent Dutch survey including 57144 S. aureus isolates, 22% were penicillin susceptible.
14 Meropenem showed good activity against methicillin-susceptible S. aureus (MIC 90 0.19 mg/L), although it was less active than imipenem (MIC 90 0.032 mg/L). The percentage meropenem-susceptible CNS was low (66%) and parallelled the low percentage of oxacillinsusceptible CNS (58%).
Three S. pneumoniae strains were relatively resistant (MIC 0.1-1 mg/L) to penicillin. No high-level penicillinresistance (MIC 2 mg/L) was found. The low prevalence of penicillin-resistance in S. pneumoniae is in agreement with the results of a recent survey in seven Dutch public health laboratories.
14 Meropenem was highly active against S. pneumoniae (meropenem MIC 90 0.016 mg/L). One S. pneumoniae strain had a high vancomycin MIC of 8 mg/L. Unfortunately, this strain was lost and the MIC could not be confirmed. Seven other S. pneumoniae strains had MICs of vancomycin of 1.5 mg/L. The MIC 90 was 1 mg/L, precisely the NCCLS vancomycin breakpoint for S. pneumoniae. Therefore, a selection of S. pneumoniae were retested at the coordinating laboratory with Etest and the reference NCCLS method (microdilution in Mueller-Hinton with 5% lysed horse blood). The MICs of vancomycin obtained with Etest were reproducible. However, the MICs of vancomycin obtained with the microdilution method were in general two two-fold dilution steps lower (data not shown). Hashemi et al. 15 have recently described similar discrepancies between results of Etest and reference methods. This is of great importance in view of the NCCLS breakpoint for susceptibility for S. pneumoniae of 1 mg/L, although most European commissions or working parties, including the Dutch, have proposed a breakpoint of 4 mg/L. Further studies to clarify this problem are currently in progress.
Two H. influenzae strains were noted resistant to imipenem, while susceptible to meropenem. Another strain was reported as resistant to piperacillin/ tazobactam and ceftazidime. Unfortunately, these strains were no longer viable for retesting with a reference method.
The percentage of inducible Enterobacteriaceae resistant to co-amoxiclav and cefuroxime was very high, reflecting the presence of chromosomal Class Ilactamases (Table III) . The percentage of E. coli that were not susceptible (thus resistant or intermediate) to co-amoxiclav was high (23%).
We screened for ESBL-producing E. coli or K. pneumoniae isolated from ICU patients using ceftazidime resistance as the selection criterion. 16, 17 Three (1.7%) ESBL-producing K. pneumoniae strains obtained from three different hospitals were found. No ESBL-producing E. coli was found. The true prevalence is probably underestimated because of difficulties in their detection. 17, 18 Inducible and non-inducible Enterobacteriaceae from ICU patients were more resistant to multiple antimicrobial agents than Enterobacteriaceae from non-ICU patients. This is particularly true for the inducible Enterobacteriaceae (Table III) . However, all inducible and noninducible Enterobacteriaceae isolated from ICU patients were susceptible to meropenem.
Nine per cent of the P. aeruginosa isolated in ICU patients were resistant or moderately susceptible to meropenem, in comparison with 11%, 14%, 14%, 21%, 25% and 34% for imipenem, ciprofloxacin, gentamicin, ceftazidime, piperacillin/tazobactam and ticarcillin/clavulanic acid, respectively.
The combination piperacillin/tazobactam was generally slightly more active than the combination ticarcillin/clavulanic acid except for Acinetobacter spp. With the latter exception, this is in agreement with a recent Dutch study. 19 Resistance percentages to gentamicin and ciprofloxacin were relatively low.
In conclusion, meropenem and imipenem had a wide spectrum of antimicrobial activity and were the most potent drugs evaluated in this study. It appears that meropenem is more active than imipenem against most Gram-negative bacteria. Both drugs showed good activity against the Gram-positive organisms tested with the exception of methicillin-resistant CNS and, in the case of meropenem in particular, enterococci. Plasmid-mediated carbapenemases have recently been described in clinical isolates of S. marcescens in Japan. 20 Therefore, postmarketing surveillance of resistance to the carbapenem antibiotics is indicated to monitor any change in susceptibility in the future. 
